EA80 - Atopic Eczema: Complete ICD-11 Coding Guide

1. Introduction

Atopic eczema, also known as atopic dermatitis, represents one of the most prevalent chronic dermatological conditions worldwide, significantly affecting the quality of life of millions of people. This chronic inflammatory dermatosis is characterized by intense pruritus, recurrent eczematous lesions, and a course marked by periods of exacerbation and remission. The condition is closely associated with atopic diathesis, frequently manifesting together with other allergic conditions such as asthma and allergic rhinitis.

The clinical importance of atopic eczema transcends its cutaneous manifestations. The condition predominantly affects children, with frequent onset in the first years of life, although it may persist or emerge in adulthood. The impact on public health is substantial, considering not only the direct costs of treatment, but also indirect costs related to loss of productivity, sleep disturbances, and significant psychological impact on patients and their families.

The correct coding of atopic eczema using the EA80 code from ICD-11 is fundamental for multiple aspects of healthcare. Accurate coding enables appropriate epidemiological tracking, facilitates proper resource allocation, ensures correct reimbursement in healthcare systems, and enables robust clinical research. Furthermore, adequate documentation is essential for longitudinal follow-up of these patients, who frequently require multidisciplinary care and prolonged treatment. Detailed understanding of diagnostic criteria and coding nuances is, therefore, indispensable for healthcare professionals involved in the management of this condition.

2. Correct ICD-11 Code

Code: EA80

Description: Atopic eczema

Parent category: Dermatitis and eczema

Official definition: Atopic eczema is a chronic inflammatory eczematous dermatosis that is genetically determined and associated with an atopic diathesis. This association manifests through elevated levels of circulating IgE, Type I allergic reactions, and frequent coexistence with asthma and allergic rhinitis. The pathogenesis of the condition involves important genetic aspects, particularly mutations in filaggrins, essential structural proteins for the epidermal barrier function. This cutaneous barrier dysfunction is fundamental to the development and perpetuation of the disease.

The clinical manifestations of atopic eczema include intense pruritus as a cardinal symptom, accompanied by exudation in acute phases, crust formation, excoriations resulting from scratching, and lichenification in chronically affected areas. The distribution pattern of lesions varies characteristically with age: in childhood, the face and non-flexural areas are frequently affected, while involvement of the flexural folds of the limbs (flexural surfaces) can be observed at any age. The natural history of the disease is variable—although it generally presents with limited extent and duration, with many patients experiencing spontaneous remission, atopic eczema can be generalized and persist throughout life in a significant proportion of cases.

3. When to Use This Code

The code EA80 should be used in specific clinical scenarios where the diagnostic criteria for atopic eczema are clearly present. Below, we present detailed practical situations:

Scenario 1: Infant with facial dermatitis and atopic family history A 6-month-old child presents with erythematous, pruritic rash on the cheeks and scalp, with exudation and crust formation. The mother reports that the child constantly scratches their face, has difficulty sleeping due to pruritus, and there is a family history of maternal asthma and paternal allergic rhinitis. Examination reveals generalized xerotic skin. This is a classic scenario for EA80 coding, as it presents the characteristic age pattern, cardinal symptoms, and familial atopic context.

Scenario 2: School-age child with chronic flexural eczema An 8-year-old patient with a history of dermatitis since infancy presents with lichenified eczematous lesions in the antecubital and popliteal fossae bilaterally. The condition shows seasonal exacerbations, worsens with certain synthetic fabrics, and the patient has a concomitant diagnosis of allergic rhinitis. Total IgE levels are elevated. The chronicity, typical flexural location, and association with other atopic manifestations fully justify the use of code EA80.

Scenario 3: Adolescent with hand eczema and personal atopic history A 15-year-old develops dermatitis on the hands with scaling, fissures, and intense pruritus. They have a personal history of atopic eczema in childhood that had gone into remission, as well as asthma controlled with medication. The current presentation represents a recurrence or persistence of atopic eczema in a different location, making code EA80 appropriate, especially considering the well-documented personal atopic history.

Scenario 4: Adult with generalized eczema and atopic markers A 30-year-old with no known previous history of eczema develops a disseminated pruritic rash with eczematous characteristics. Investigation reveals very elevated serum IgE levels, positive skin tests for multiple aeroallergens, and a history of allergic rhinitis since adolescence. Skin biopsy shows findings compatible with eczematous dermatitis. Despite late onset, the atopic markers and clinical characteristics justify code EA80.

Scenario 5: Pediatric patient with atopic eczema and secondary infection A 4-year-old with diagnosed atopic eczema presents with acute exacerbation with areas of purulent exudation, meliceric crusts, and low-grade fever, suggestive of secondary impetiginization. The primary code remains EA80, and may be complemented with an additional code for secondary bacterial infection, appropriately documenting both conditions.

Scenario 6: Infant with atopic dermatitis resistant to initial treatment A 10-month-old with facial and trunk dermatitis unresponsive to basic moisturizers, presenting with progressive worsening and development of early lichenification. Maternal history of severe atopic eczema in childhood. The severity and treatment refractoriness do not alter the diagnostic code EA80, but should be appropriately documented to justify more advanced therapies.

4. When NOT to Use This Code

It is essential to recognize situations where code EA80 is not appropriate, avoiding coding errors that may compromise medical records and epidemiological statistics.

Allergic or irritant contact dermatitis: When the skin rash clearly results from exposure to specific substances (metals, cosmetics, cleaning products) without atopic context, specific codes for contact dermatitis should be used. Differentiation is based on clear exposure history, contact-related distribution pattern, and absence of atopic markers.

Seborrheic dermatitis: Erythematous scaly lesions in seborrheic areas (scalp, nasolabial folds, central chest region) in adults, especially without atopic history or intense pruritus, should be coded as EA81. Differentiation is crucial, as seborrheic dermatitis presents characteristic oily yellowish scales, specific distribution, and distinct pathophysiology.

Psoriasis: Well-demarcated erythematous plaques with silvery scaling, especially on extensor surfaces (knees, elbows), should not be confused with atopic eczema. Psoriasis has its own code and distinct histopathological characteristics.

Nummular eczema (EA82): When lesions present as well-defined circular or oval plaques, coin-like, without the typical distribution pattern of atopic eczema and frequently without significant atopic history, code EA82 is more appropriate.

Chronic simple lichen (EA83): Localized lichenification resulting from chronic mechanical trauma (scratching, rubbing) in a specific area, without the context of generalized atopic dermatitis or atopic history, should be coded as EA83. This condition represents a cutaneous response to repetitive trauma, not necessarily related to atopic diathesis.

Dermatitis herpetiformis: Intensely pruritic vesicular eruption associated with celiac disease requires a specific code and should not be confused with atopic eczema despite intense pruritus.

5. Step-by-Step Coding Process

Step 1: Assess diagnostic criteria

The confirmation of atopic eczema diagnosis is based on well-established clinical criteria. The healthcare professional must systematically investigate the presence of major and minor criteria. Among the essential criteria are: pruritus as a fundamental symptom (without pruritus, atopic eczema diagnosis is questioned), typical morphology and distribution of lesions (facial and extensor eczema in infants, flexural eczema in older children and adults), chronic or chronically recurrent course, and personal or family history of atopy.

The evaluation should include detailed clinical history investigating symptom onset, temporal evolution, identified triggering factors, history of other atopic conditions (asthma, allergic rhinitis, food allergies), and family history of atopy. Physical examination should document lesion morphology (erythema, exudation, crusts, excoriations, lichenification), anatomical distribution, presence of generalized cutaneous xerosis, and associated signs such as Dennie-Morgan infraorbital fold or perioral pallor.

Standardized assessment instruments may assist in documenting severity, including scores such as SCORAD (Scoring Atopic Dermatitis) or EASI (Eczema Area and Severity Index), which quantify extent and intensity of lesions. Although not mandatory for diagnosis, these instruments are valuable for longitudinal follow-up and research.

Step 2: Verify specifiers

After confirming atopic eczema diagnosis, the clinical presentation should be adequately characterized. Severity should be documented, classifying the condition as mild, moderate, or severe based on the extent of skin involvement, symptom intensity, and impact on quality of life. This information, although it does not change the main code EA80, is crucial for justifying therapeutic choices.

Duration and evolutionary pattern should be recorded: first manifestation versus established disease, acute exacerbation phase versus stable chronic phase, presence of remissions and their duration. Specific characteristics such as presence of secondary infection, areas of significant lichenification, or involvement of special areas (hands, eyelids) merit detailed documentation.

Associated atopic comorbidities should be identified and coded separately when present, including asthma, allergic rhinitis, allergic conjunctivitis, and food allergies. This complete documentation provides a comprehensive overview of the patient's atopic condition.

Step 3: Differentiate from other codes

EA81 - Seborrheic dermatitis and related conditions: The main difference lies in the distribution of lesions and morphological characteristics. Seborrheic dermatitis preferentially affects areas rich in sebaceous glands with oily yellowish scales, while atopic eczema presents more xerotic, pruritic lesions with characteristic flexural distribution in older children. Personal or family atopic history favors EA80.

EA82 - Nummular dermatitis: Differentiated by lesion morphology in well-demarcated circular or oval plaques, coin-like, frequently on lower limbs or dorsal surface of hands. Although it may occur in atopic patients, when nummular lesions are the predominant presentation without other characteristics of atopic eczema, EA82 is more appropriate.

EA83 - Simple lichen or lichenification: Represents localized lichenification from chronic mechanical trauma in a specific area, without the systemic context of atopy. When lichenification occurs as part of atopic eczema in typically affected areas (antecubital and popliteal fossae) with clear atopic history, EA80 remains the correct code.

Step 4: Necessary documentation

Adequate documentation should include: detailed description of skin lesions (morphology, distribution, extent), record of pruritus intensity and its impact on sleep and daily activities, history of onset and temporal evolution, personal history of other atopic manifestations, family history of atopy, identified triggering factors, previous treatments and response, and quality of life assessment.

When available, results of complementary tests should be recorded: total IgE levels (frequently elevated, but not mandatory for diagnosis), cutaneous or serum allergy tests when performed, and results of skin biopsy if performed (although rarely necessary, it may show characteristic spongiosis and inflammatory infiltrate).

Photographic documentation of lesions, when possible and with appropriate consent, constitutes a valuable tool for evolutionary follow-up. All this information supports EA80 coding and provides robust justification for therapeutic decisions.

6. Complete Practical Example

Clinical Case:

Maria, a 3-year-old girl, is brought to the appointment by her mother with a complaint of "skin allergy" that has been progressively worsening for 6 months. The mother reports that since 4 months of age Maria has presented episodes of redness on her cheeks, which would improve and worsen spontaneously. At 2 years old, she developed lesions on her arms that itched a lot, interfering with sleep. Currently, she presents significant worsening with lesions that "become wet" and then form crusts.

In the clinical history, the mother mentions that Maria has had "bronchitis" since 1 year of age, occasionally using a bronchodilator, and frequently sneezes in the morning. The father has diagnosed allergic rhinitis and the maternal grandmother had asthma in childhood. Maria frequently wakes up at night scratching herself, is irritable, and the mother notes that certain wool clothing worsens the condition.

On physical examination, the child is observed to be in good general condition, anxious, frequently scratching during the appointment. Skin with generalized xerosis. Presence of poorly demarcated erythematous plaques in the antecubital fossae bilaterally, with areas of lichenification, superficial excoriations from scratching, and some areas with serous exudation. Popliteal fossae present erythema and fine desquamation. Face with discrete perioral erythema. Dorsum of hands with dry skin and some erythematous papules. No lesions in seborrheic areas or isolated circular plaques.

Complementary tests requested previously show total IgE of 850 IU/mL (elevated for age). Complete blood count with mild eosinophilia. The evaluation using SCORAD score indicates moderate to severe eczema.

Step-by-Step Coding:

Analysis of criteria:

Intense pruritus: present, interfering with sleep (essential criterion confirmed)
Typical morphology: eczematous lesions with erythema, exudation, excoriations, lichenification (confirmed)
Characteristic distribution: antecubital and popliteal fossae (typical flexural pattern for age) (confirmed)
Chronic-recurrent course: onset at 4 months, evolution with periods of improvement and worsening, current aggravation (confirmed)
Personal history of atopy: respiratory symptoms suggestive of asthma (confirmed)
Family history of atopy: father with allergic rhinitis, grandmother with asthma (confirmed)
Cutaneous xerosis: present in generalized form (confirmed)
Laboratory marker: elevated IgE (additional support)

Code chosen: EA80 - Atopic eczema

Complete justification: The diagnosis of atopic eczema is fully established by the presence of all major criteria: pruritus as a cardinal symptom with significant impact on quality of life, classic eczematous morphology with multiple characteristics (erythema, exudation, crusts, excoriations, lichenification), typical distribution for the age group with predominantly flexural involvement, chronic course since childhood with recurrent pattern, and robust atopic context both personal (respiratory symptoms) and familial.

The elevation of serum IgE, although not mandatory for diagnosis, corroborates the atopic context. Generalized xerosis represents a characteristic manifestation of the cutaneous barrier dysfunction typical of atopic eczema. The identification of triggering factors (wool clothing) and the pattern of nocturnal worsening are consistent with the diagnosis.

Applicable complementary codes:

Additional code for asthma (if confirmed by spirometry or specialist evaluation)
Code for secondary bacterial infection if there is evidence of impetiginization in exudative areas (to be confirmed by clinical evaluation or culture if necessary)

Recorded documentation: Moderate to severe atopic eczema, with predominantly flexural involvement, phase of acute exacerbation with exudation, in a patient with significant personal and family atopic history. SCORAD: moderate to severe. Intensive emollients treatment recommended, medium-potency topical corticosteroid for affected areas, and evaluation for possible secondary infection. Guidance on skin care, identification and avoidance of triggers, and regular follow-up established.

7. Related Codes and Differentiation

Within the Same Category:

EA81: Seborrheic dermatitis and related conditions

When to use EA81 vs. EA80: Seborrheic dermatitis should be coded as EA81 when lesions present specific characteristics of this condition: oily yellowish scales, distribution in seborrheic areas (scalp, nasolabial folds, retroauricular region, central chest region), absence of intense pruritus or mild to moderate pruritus intensity, and generally without significant atopic context.

Main difference: Seborrheic dermatitis relates to sebaceous gland activity and frequently to Malassezia colonization, presenting characteristic oily scales, whereas atopic eczema associates with cutaneous barrier dysfunction and atopic diathesis, with more xerotic lesions and much more intense pruritus. In infants, there may be overlap ("cradle cap" with atopic component), but the predominant pattern guides coding.

EA82: Nummular dermatitis

When to use EA82 vs. EA80: Code EA82 is appropriate when lesions present as well-defined circular or oval eczematous plaques, coin-like, frequently on lower limbs or extensor surfaces, without the flexural distribution pattern of atopic eczema. It may occur in patients without significant atopic history or as an isolated manifestation.

Main difference: The distinctive morphology in well-demarcated circular plaques versus the diffuse or flexural pattern of atopic eczema. When a patient with established atopic eczema develops nummular lesions, the overall clinical context determines whether EA80 remains as the principal code or whether EA82 should be added to characterize this specific presentation.

EA83: Lichen simplex or lichenification

When to use EA83 vs. EA80: Chronic lichen simplex (EA83) represents localized lichenification resulting from repetitive mechanical trauma (scratching, rubbing) in a specific area, functioning as a cutaneous response to chronic trauma. It typically occurs in a single area accessible to scratching (nape of neck, ankles, anogenital region), without the systemic context of atopy.

Main difference: Lichen simplex is localized and represents response to mechanical trauma, whereas atopic eczema is a systemic condition with genetic predisposition and multiple affected areas. When lichenification occurs in a patient with atopic eczema in typically affected areas (antecubital fossae, popliteal fossae), it remains as a manifestation of EA80, not requiring a separate code.

Differential Diagnoses:

Allergic contact dermatitis: Distinguished by clear history of exposure to specific allergen, distribution of lesions corresponding to the contact area, and possibility of confirmation by contact testing (patch tests). It may coexist with atopic eczema, as atopic patients have greater susceptibility to contact sensitization.

Psoriasis: Differentiated by well-demarcated plaques with silvery scale, preferential distribution on extensor surfaces, characteristic nail involvement, and absence of intense pruritus in most cases. Histopathology is distinctive when necessary.

Scabies: Intense nocturnal pruritus may simulate atopic eczema, but the presence of specific lesions (burrows), characteristic distribution (interdigital spaces, wrists, axillae, genital region), and involvement of contacts aid in differentiation.

Dermatophytosis: Annular lesions with active scaly border and cleared center, generally asymmetric, with confirmation by direct mycological examination and culture.

8. Differences with ICD-10

In ICD-10, atopic eczema was coded primarily as L20.9 (Unspecified atopic dermatitis) or more specific subcategories such as L20.0 (Besnier's prurigo) or L20.8 (Other atopic dermatitis). ICD-10 offered subdivisions based on specific clinical presentations within the L20 category.

ICD-11 introduces significant changes in conceptual organization. The code EA80 represents a more unified approach, recognizing atopic eczema as a single entity with variations in presentation, rather than multiple subcategories. This change reflects contemporary understanding that diverse presentations (infantile, flexural, etc.) represent manifestations of the same condition at different ages and evolutionary stages.

ICD-11 more clearly emphasizes the genetic basis (filaggrin mutations) and association with atopic diathesis in the code definition itself. The preferred terminology changed to "atopic eczema" instead of "atopic dermatitis," although both terms remain recognized as synonyms.

The practical impact of these changes includes simplification of coding, eliminating the need to choose among multiple ICD-10 subcategories. Professionals should be attentive during the transition period, as electronic health record systems may still utilize ICD-10 codes, requiring appropriate conversion. Documentation should be sufficiently detailed to allow adequate mapping between systems when necessary.

For statistical and epidemiological purposes, studies that used ICD-10 codes can be compared with ICD-11 data using EA80, recognizing that this code essentially encompasses what was categorized under L20 and its subdivisions in the previous classification.

9. Frequently Asked Questions

1. How is atopic eczema diagnosed?

The diagnosis of atopic eczema is essentially clinical, based on history and physical examination. There is no single laboratory test that confirms or excludes the diagnosis. The physician evaluates the presence of established diagnostic criteria: pruritus as a fundamental symptom, typical morphology of lesions (erythema, exudation, crusts, excoriations, lichenification), characteristic distribution according to age (face and extensor surfaces in infants, flexural areas in older children and adults), chronic or chronically recurrent course, and personal or family history of atopic conditions. Complementary tests such as total IgE measurement, allergy tests, or rarely skin biopsy may provide additional information, but are not mandatory for diagnosis in most cases. Evaluation by a dermatologist or allergist may be necessary in atypical, severe, or treatment-refractory cases.

2. Is treatment available in public health systems?

Treatment of atopic eczema is generally available in public health systems at different levels of complexity. Fundamental treatments include moisturizers and emollients for restoration of the skin barrier, topical corticosteroids of different potencies for inflammation control, and oral antihistamines for pruritus relief. These medications are usually included in essential medication lists. For moderate to severe cases that do not respond to conventional treatments, more advanced therapies such as topical calcineurin inhibitors, phototherapy, or systemic immunosuppressants may be necessary. The availability of newer treatments, such as biologic medications, varies considerably among different health systems and frequently requires specialized evaluation and justification based on specific criteria of severity and treatment refractoriness. Access to dermatologists and allergists within public systems also varies, and there may be waiting times for specialized evaluation.

3. How long does treatment last?

The duration of treatment for atopic eczema varies widely depending on the severity of the condition and individual response. Atopic eczema is a chronic condition, therefore "treatment" frequently means ongoing management rather than definitive cure. Basic skin care, especially regular moisturization with emollients, should generally be maintained indefinitely, even during periods of remission, to preserve skin barrier function. During acute exacerbations, anti-inflammatory topical treatments (corticosteroids or calcineurin inhibitors) are used for limited periods, typically days to a few weeks, until active lesions are controlled. Many children experience significant improvement or complete remission with growth, often during adolescence, although a substantial proportion continue to present symptoms in adulthood. Regular medical follow-up allows therapeutic adjustments as needed and early identification of complications such as secondary infections.

4. Can this code be used in medical certificates?

Yes, the code EA80 can and should be used in official medical documentation, including certificates when appropriate. In certificates to justify school or work absences, especially during severe exacerbations that significantly compromise function or require intensive treatments, the inclusion of the ICD-11 code provides objective documentation of the condition. It is important to emphasize that the need for leave should be determined by the severity of the current condition, not simply by the presence of the diagnosis. Severe exacerbations with extensive lesions, secondary infection, or significant sleep impairment may justify temporary leave. For children, exacerbations may interfere with school activities, especially when involving the face or hands, or when newly initiated treatments require dose adjustment and close monitoring. Documentation should specify the current phase of the disease (acute exacerbation versus stable chronic disease) to appropriately contextualize the need for leave or restrictions.

5. Can atopic eczema be permanently cured?

Currently, there is no definitive cure for atopic eczema, as it is a condition with a genetic basis involving mutations in structural skin proteins (filaggrins) and immunological predisposition. However, the natural history of the disease is often favorable, with many children experiencing spontaneous remission or significant improvement with growth. Studies suggest that a considerable proportion of children with atopic eczema present complete or near-complete resolution of symptoms by adolescence or early adulthood. Even without cure, adequate control with available treatments allows excellent quality of life for most patients. Ongoing research investigates therapies targeting specific disease mechanisms, including biologic medications that block specific inflammatory pathways, offering hope for even better control, especially for severe cases. Appropriate management, including skin care, identification and avoidance of triggers, and judicious use of medications, allows significant minimization of the condition's impact.

6. What factors can trigger or worsen atopic eczema?

Multiple factors can trigger exacerbations of atopic eczema. Direct skin irritants include harsh soaps, detergents, cleaning products, rough or synthetic fabrics, and prolonged water exposure (very frequent or prolonged baths). Environmental allergens such as house dust mites, pollen, animal dander, and fungi can cause worsening in sensitized patients. Foods can be triggers in some children, particularly infants and young children, with the most common being cow's milk, egg, wheat, soy, peanut, and seafood. Climatic factors include low air humidity (worsening skin xerosis), extreme cold, and excessive sweating in hot climates. Infections, especially viral respiratory infections, can precipitate exacerbations. Emotional stress is recognized as a significant aggravating factor. Identifying specific triggers for each patient allows personalized avoidance strategies, although it is not always possible to identify specific factors for all exacerbation episodes.

7. Is there a relationship between atopic eczema and other allergic diseases?

Yes, there is a strong association between atopic eczema and other manifestations of atopy, a concept known as the "atopic march." Children with atopic eczema present increased risk of subsequently developing other allergic conditions. Many develop food allergies, particularly in the first years of life. Later, there is increased risk of developing allergic rhinitis and asthma, often in this temporal sequence. This progression is not inevitable, but sufficiently common to justify surveillance. The presence of severe and early-onset atopic eczema is associated with greater risk of development of other atopic manifestations. Understanding this association is important for family counseling, appropriate monitoring for development of other allergic conditions, and potentially for preventive interventions. Some studies suggest that rigorous control of atopic eczema from the beginning may potentially reduce the risk of progression to other atopic manifestations, although this hypothesis is still being investigated.

8. Can children with atopic eczema attend swimming pools?

Children with atopic eczema can attend swimming pools, but with specific precautions. The chlorine present in pool water can act as an irritant, potentially triggering exacerbations or worsening existing lesions. However, with appropriate care, many children tolerate this activity well. Recommendations include: apply a generous layer of emollient before entering the pool, creating a protective barrier; limit exposure time; rinse immediately after leaving the pool with warm water to remove chlorine; reapply moisturizer generously after bathing. Avoiding pools during acute exacerbations with open or exudative lesions is prudent, both for the child's comfort and to prevent secondary infection. Pools with salt water or alternative treatment systems may be better tolerated by some patients. The decision should be individualized, balancing the benefits of physical activity and socialization against potential skin irritation, always with guidance from the attending physician.

Conclusion:

The code EA80 from ICD-11 for atopic eczema represents an essential tool for accurate documentation of this prevalent chronic dermatological condition. Appropriate coding requires understanding of diagnostic criteria, recognition of presentation patterns in different age groups, and careful differentiation from other dermatological conditions. With adequate documentation and correct use of code EA80, health professionals contribute to accurate epidemiological records, facilitate communication between health teams, ensure appropriate reimbursement processing, and support evidence-based therapeutic decisions for better care of patients with this impactful condition.

External References

This article was developed based on reliable scientific sources:

References verified on 2026-02-03

Atopic Eczema

Compartilhar